Molecules that control the lineage commitment of hematopoietic stem cells (HSCs) may allow the expansion of enriched progenitor populations for both research and therapeutic uses. In an effort to better understand and control the differentiation of HSCs to megakaryocytes, we carried out an image-based screen of a library of 50,000 heterocycles using primary human CD34 + cells. A class of naphthyridinone derivatives was identified that induces the differentiation of common myeloid progenitors (CMP) to megakaryocytes. Kinase profiling and subsequent functional assays revealed that these compounds act through inhibition of platelet-derived growth factor receptor (PDGFR) signaling in CMPs. Such molecules may ultimately have clinical utility in the treatment of thrombocytopenia.
H ematopoietic stem cells (HSCs) are among the best-characterized adult stem cells and have been used clinically for over 30 years in bone-marrow transplantation (1) . Nonetheless, therapeutic applications of HSCs remain limited by a lack of robust, well-defined conditions for their self-renewal and directed differentiation. Recently, we and others identified small molecules and proteins for the ex vivo expansion of both human adult and umbilical-cord blood-derived HSCs (2, 3) . For example, a purine derivative was identified that expands CD34 + cells by antagonizing the aryl hydrocarbon receptor; the expanded cells engraft efficiently in an nonobese diabetic (NOD) SCID gamma mouse model (4) . Similarly, small molecules that control the differentiation of CD34 + cells to megakaryocyte or red-blood-cell lineages might be used in the treatment of genetic blood diseases and cancer, or enable the production of blood products ex vivo. In particular, we have developed a high-throughput image-based screen to identify small molecules that control the differentiation of human CD34 + cells to megakaryocytes. Such molecules should prove useful tools for elucidating the underlying cellular processes that regulate megakaryopoiesis. In addition, transplantation of ex vivo expanded megakaryocytic progenitor cells might provide a strategy for shortening the duration of thrombocytopenia associated with high-dose chemotherapy and hematopoietic stem-cell transplantation (5) . Indeed the number of megakaryocytic progenitors present in transplants has been correlated with platelet recovery (6) , and several clinical trials using expanded peripheral blood stem cells and bone marrow have demonstrated success in alleviating thrombocytopenia after high-dose chemotherapy (7, 8) .
Mixtures of hematopoietic growth factors have been developed for the ex vivo expansion of megakaryocytes. Although thrombopoietin (TPO) is clearly the major physiological regulator of this process (9) , several other cytokines, including interleukins-3, -1, -11, and -6, granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor, have been shown to be important for normal platelet formation (10) . In contrast to TPO, which acts throughout megakaryopoiesis, these cytokines affect megakaryopoiesis during the early stages of megakaryocyte development. However, even the best-reported conditions for the ex vivo production of hematopoietic lineages yield a low percentage of megakaryocyte precursors (< 5-15%) (11) . Here we report the identification of a class of small molecules that directs CD34 + cell differentiation down the megakaryocyte lineage by high-throughput cell-based screening of primary human CD34 + cells. The physiological target of these molecules appears to be platelet-derived growth factor receptor (PDGFR), and modulation of this signaling pathway may be useful to facilitate ex vivo megakaryocyte expansion for therapeutic applications.
Results and Discussion
High-Throughput Chemical Screen. One limitation in identifying signals that promote megakaryopoiesis is a lack of suitable cell-line models. To overcome this we developed a low-volume highthroughput screen using advanced automation and imaging technologies. These features allow screens to be conducted on purified human CD34 + cells isolated from mobilized peripheral blood (mPB) from normal donors. To identify compounds that increase megakaryopoiesis, human CD34 + cells were cultured under conditions optimized for HSC expansion [serum-free media supplemented with TPO, stem cell factor, Flt3 ligand, and interleukin-6 (IL-6)] (12), and assayed for compounds that increase the number of CD41 + cells [CD41 is a selective megakaryocyte marker (13)]. When cultured under these conditions, CD34
+ cells spontaneously differentiate into all of the different blood lineages, and depending on the donor, generate 3-15% megakaryocytes (based on CD41 expression) at 6 d. Adding IL-9, IL-11, or erythropoietin (EPO), three cytokines previously reported to increase megakaryocyte expansion (11, (14) (15) (16) (17) , to these four growth factors did not result in a higher number of megakaryocytes relative to input CD34+ cells (Fig. S1A) . To carry out the screen, mPB CD34 + cells were plated into 1,536-well plates at a density of 250 cells per well in HSC expansion media, and on the same day, compounds from a library of 50,000 discrete heterocycles (18) were added (1 μM final concentration in 0.1% DMSO). After 6 d of incubation, the cells were immunostained for CD41 and CD71 expression (Fig.  1A) . From the primary screen, a naphthyridinone (MK1, Fig. 1B ) was identified that increases the percentage of CD41 + cells in a dose-response fashion ( Fig. 1 C and D) . At the optimal dose (EC 90 = 750 nM), MK1 increased the absolute number of CD41 + cells threefold.
Characterization of Biological Activity. Ploidy analysis was carried out to ensure that the CD41 + cells were megakaryocytes. Megakaryocytes are 10-15 times larger than a typical red blood cell, averaging 50-100 μm in diameter (19) . During its maturation, the megakaryocyte grows in size and replicates its DNA without cytokinesis (19) ; as a result, the nucleus of the megakaryocyte can become very large and lobulated, and in some cases, may contain up to 64N DNA, or 32 copies of the normal complement of DNA in a human cell. After 10 d in cell culture, mPB CD34 + cells treated with 0.75 μM MK1 showed a greater than twofold increase To whom correspondence may be addressed. E-mail: schultz@scripps.edu or tboitano@ gnf.org.
in the populations of CD41 + cells in the G1 (2N), G2 (4N), and greater than G2 (>4N) phase, consistent with formation of the megakaryocyte lineage ( Fig. 1 C and D) . The megakaryocyte precursors generated from MK1 treatment were also tested for their ability to generate megakaryocyte colonies (CFU-MK) in semisolid media optimized for megakaryocyte colony growth. After 8 d, 5,000 mPB CD34 + cells expanded with vehicle (DMSO, 0.1%) or MK1 (0.5 μM) were assayed for CFU-Mk content. MK1-treated cells generated a three-to fourfold increase in megakaryocyte colonies compared with vehicle alone, which indicates that compound treatment generates more megakaryocyte precursors that are able to differentiate and form colonies ( Fig. 1 E and F) .
Differentiation of CD34 + cells to megakaryocytes involves progression through several different progenitor populations (20) . The current model of hematopoiesis involves differentiation of the multipotent HSC to the common myeloid progenitor (CMP), which then differentiates into either granulocyte/monocyte progenitors (GMP) or megakaryocyte/erythrocyte progenitors (MEP). Each of these populations can be identified by flow cytometry using cell-surface markers (21) (Fig. S1B) . To determine the effect of MK1 on HSC differentiation, cells were cultured for 10 d with MK1 and analyzed by flow cytometry (Fig. 2 ). This analysis revealed that MK1 promotes an increase in MEPs at the expense of GMPs ( Fig. 2 C and D). Loss of GMPs is accompanied by a decrease in granulocytes and monocytes ( Fig. 2 E and F) . Cultures were performed in the presence of erythropoietin [EPO, a cytokine that is required for proliferation of erythrocyte precursors (22) ] to determine if MK1 also impacts erythropoiesis (Fig. S2 ). As expected, EPO generated a robust expansion of erythroid progenitors. Including MK had no impact on erythropoiesis, but did result in the decrease of GMPs and an increase in MEPs and megakaryocytes as observed in the absence of EPO. These data suggest MK1 is directing CMPs down the MEP pathway.
To determine if MK1 acts directly on CMPs to increase megakaryopoiesis, CMPs, MEPs, and GMPs were purified by FACS from mPB CD34 + cells following culture in expansion media for 5 d (Fig. S1B) , and the progenitor populations were cultured for an additional 5 d in the absence or presence of MK1. Treatment of CMPs with MK1 resulted in an increase in megakaryocyte differentiation similar to that seen in cultures initiated with CD34 + cells ( Fig. S3 A and D) . Flow-cytometry analysis revealed the cells were able to differentiate into both GMPs and MEPs (Fig. S3 B and C), confirming that the isolated cells were CMPs. These effects were also seen in the presence of EPO (Fig. S3) , which further indicates that MK1 does not adversely affect erythrocyte differentiation (see Fig. S3D ). MK1 (0.75 μM) had no effect on the proliferation or differentiation of purified GMPs, and very few (< 1%) CD41 + or GlyA + cells were present (Fig. S4) . Finally, treatment of MEPs with MK1 in the absence of EPO led to a modest increase in megakaryocytes and a reduction in GlyA + erythrocyte progenitors (Fig. S5) . Supplementing MEP cultures with EPO + MK1 resulted in a greater than twofold increase in CD41 + cells and the number of erythroid progenitors was unchanged (Fig. S5) .
Taken together, our results show that MK1 promotes megakaryopoiesis from both CMP and MEPs. We observed that cultures initiated with CMPs showed a less-marked MK1-induced MEP increase compared with cultures initiated with HSCs. This may result from the difference in treatment duration (5 versus 10 d, respectively). It may also be the case that within a population of sorted CMPs, many cells are already primed toward either the MEP or the GMP lineage. In contrast, in cultures initiated with HSCs, every newly generated CMP is naïve, resulting in a larger pool of cells that are potentially MK1 responsive.
Mechanism of Action. To identify the mechanism by which MK1 increases megakaryopoiesis, we carried out kinase-profiling experiments. The top 12 hit compounds confirmed from the primary screen (based on EC 50 values) were analyzed using a panel of activated tyrosine-kinase-dependent cellular assays described by Melnick et al. (23) . Briefly, the compounds were tested against a panel of Ba/F3 cell lines stably expressing different TEL-tyrosine kinase fusions, on whose activity they depend for survival. The compounds were found to inhibit growth of the cell lines expressing the PDGFR-TEL fusion. A correlation (R 2 = 0.82) between activity in the mPB CD34 + cell assay and inhibition of PDGFR (Fig. 3A) was observed, which suggests that MK1 may affect megakaryocyte differentiation via inhibition of PDGFR signaling. The PDGF family of growth factors consists of five different disulfide-linked dimers composed of four different polypeptide chains encoded by four different genes (24, 25) . These isoforms, PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD act through two receptor tyrosine kinases PDGFRs (α and β) that form three dimeric isoforms (αα, αβ, and ββ) (26) .
Based on the results of the kinase-profiling experiment, we used quantitative PCR to investigate expression of the PDGFRs and different PDGF isoforms in cultivated CD34 + cells and their progeny. This analysis showed that PDGF-CC is the predominant form of PDGF expressed during the first 7 d of CD34 + cell culture (the time frame in which we begin to observe the effect) (Fig. S6A) . PDGF-AA and -BB are not expressed until day 7 of culture. PDGFR-α and -β are not expressed at high levels on freshly isolated CD34+ cells, but are present on isolated CMPs and on CD41 + cells, consistent with the ability of MK1 to affect megakaryocyte differentiation at the CMP stage (Fig. S6B) .
Based on these gene expression observations, we investigated the hypothesis that inhibition of PDGFR signaling was responsible for the effect of MK1 on megakaryopoiesis, by using neutralizing antibodies to the different PDGFs. The addition of neutralizing antibodies against PDGF-CC (200 μg/mL) to the culture also promoted megakaryopoiesis in a manner similar to MK1 (Fig. 3B) ; whereas, neutralizing antibodies against PDGF-AA and -BB had a lower effect. Neutralization of PDGF-CC increased both the percentage of CD41 + cells and the absolute number of CD41 + cells two-to threefold ( Fig. 3 B and C and Fig. S7 ). Including the anti-PDGF-CC antibody also resulted in increased number of high ploidy (>4N) cells and of CFU-Mk (Fig. 3 C-E) . Like MK1, anti-PDGF-CC increased the number of MEPs and led to a reduction in GMP number (Fig. S7) . Treatment of isolated CMPs with anti-PDGF-CC increased megakaryopoiesis (Fig. S8 ). In addition, anti-PDGF-CC increased the number of megakaryocytes (∼25%) from purified MEPs similarly, and had no effect on GMPs (Fig.  S8) . Finally, cotreatment with MK1 and anti-PDGF-CC neutralizing antibody did not show any additive effect on megakaryopoiesis (Fig. S9A) . These experiments strongly support the hypothesis that PDGFR is the biological target of MK1 that is responsible for increased megakaryopoiesis. Finally, to confirm the hypothesis that MK1 is a PDGFR inhibitor, we measured the ability of MK1 to inhibit PDGF-CCmediated PDGFR phosphorylation in U138-malignant glioma (MG) cells, a glioblastoma cell line expressing high levels of PDGFR. Pretreatment with MK1 significantly and dose-responsively lowered the levels of phosphorylated PDGFR measured in these cells after a 10-min PDGF-CC stimulation (Fig.  S9B) . MK1 also inhibited the PDGF-CC-induced phosphorylation of PLCγ1, a major downstream target of PDGFR (Fig. S9C) .
Taken together, these data suggest that PDGF-CC is expressed throughout CD34 + cell differentiation and acts on CMPs to inhibit megakaryopoiesis. Inclusion of the PDGFR antagonist MK1 counteracts these effects thereby promoting megakaryocyte differentiation. The observation that PDGF-CC is expressed by CD34 + cells may explain why previous efforts supplementing cultures with exogenous PDGF failed to identify a role for PDGF in megakaryopoiesis (27) . The observation that the action of MK1 happens at the expense of GM differentiation, but not at the expense of erythrocyte differentiation, further supports the notion that MK1 acts at the CMP stage. Despite unchanged total cell numbers, a larger proportion of MK1 and anti-PDGF-CC-treated cells remained CD34+ (Fig. 2 and Fig. S7 ), suggesting that antagonizing PDGF-CC activity may slow down the differentiation process. The vast majority of the remaining CD34+ cells are CMPs, indicating that cells may encounter a bottleneck at that stage. This is consistent with our observation that PDGF-CC antagonism blocks differentiation to the GMP lineage, thereby reducing the possible outlets available to CMPs, and suggests that MK1 skews but does not accelerate CMP differentiation, causing an accumulation of cells in the CMP stage. In contrast, the MEP stage seems to be much more transient, at least in culture, as their levels appear repeatedly much lower than their CMP progenitors or their CD41+ progeny.
Feedback inhibition of megakaryocyte differentiation by PDGF has interesting parallels to the regulation of megakaryocyte and platelet production by TPO. In this system, the amount of free TPO is regulated by TPO receptors on platelets. As platelet numbers increase, the amount of bioavailable TPO is reduced, leading to decreased megakaryopoiesis. PDGF is also highly expressed by platelets and it is tempting to speculate that PDGF may also inhibit megakaryopoiesis in vivo especially when platelet levels are high. Because the effect of MK1 is observed in the presence of saturating TPO, PDGFR inhibition may provide a unique approach to increase platelets in thrombocytopenic patients alone or in combination with TPO. FITC anti-CD45RA (e-Bioscience), PECy7 anti-CD41 (BD Bioscience), and PE anti-GlyA (BD Bioscience), then washed with staining media and analyzed.
Materials and Methods
Determination of Hematopoietic Cell Subsets. The percentages of indicated cell subsets were determined from aliquots of the cell culture at each time point. Flow-cytometry results of these subsets are given as percentage of the total population. The total cell number in each treatment group was determined by trypan blue exclusion. Absolute numbers of each population in the culture were calculated from the total number of cells multiplied by the percentage of each population.
Colony-Forming Assays. CFU-MKs were generated by seeding cells into the MegaCult-detect megakaryocyte progenitor kit (StemCell Technologies) following manufacturer's instructions. Colonies were scored on day 12 with an inverted microscope at 40× magnification. Colony content of the expansion culture was calculated as follows: the average number of scored colonies from three dishes × total mononuclear cell number/input cell number. Total mononuclear cells were determined by multiplying the number of cells per milliliter by the culture volume.
Ploidy. Cells were harvested and washed with staining media. They were then labeled with FITC anti-human CD41. After washing, the cells were resuspended in paraformaldehyde (2%) and incubated at room temperature for 10 min before the addition of DAPI (1 μg/mL) for another 10 min. The cells were washed and analyzed by flow cytometry.
Kinase Profiling. The activated tyrosine-kinase-dependent Ba/F3 cellular assays were described by Melnick et al. (23) .
PDGFR Phosphorylation Assays. U138-MG cells were cultivated in DMEM + 10% FBS. Before the experiment, cells were serum starved overnight then treated with MK1 or vehicle at the indicated concentrations, and incubated for a minimum of 30 min at 37°C. PDGF-CC was then added to the cultures to a final concentration of 100ng/mL After 10 min of incubation at 37°C, cells were washed with cold PBS, then lysed. The lysis buffer used depended on the downstream application: ELISA or Western blot (see below).
ELISA. Cell lysis and all subsequent steps were performed with the following kits, according to the manufacturer's instructions: Pathscan Phospho-PDGF receptor α/β (panTyr) sandwich ELISA kit (7235; Cell Signaling) and Pathscan total PDGF receptor α sandwich ELISA kit.
Western Blots. Cells were lysed with 100 μL of RIPA buffer supplemented with a protease inhibitor mixture (Sigma). Following incubation on ice for 20 min, the lysed cells were passed through a 261/2 syringe needle and centrifuged (15,000 g, 20 min at 4°C). Cell lysates were denatured by boiling in SDS sample buffer (Invitrogen) containing 5% β-mercaptoethanol. Proteins were electrophoresed, transferred onto a PVDF membrane and probed with anti-PLCγ1 (2822; Cell Signaling) or anti-phospho-PLCγ1 (2821; Cell Signaling) antibodies at suggested concentrations in tris-buffered saline containing 0.1% tween 20 and 5% (vol/vol) BSA. Blots were then incubated with HRPconjugated secondary antibodies and detected with a chemiluminescent substrate (Thermo Scientific).
qPCR Analysis. RNA was extracted using RNAeasy Mini Kit (Qiagen) according to the manufacturer's instructions. Purified RNA was subjected to cDNA synthesis using Quantitect Reverse Transcription Kit (Qiagen) according to the manufacturer's instructions. The cDNA served as a template for the amplification of PDGF-a, PDGF-b, PDGF-c, PDGF-d, PDGFR-α, PDGFR-β, and the housekeeping gene TATA binding protein (TBP) by real-time PCR, using a 384-well plate in a total volume of 12.5 μL, which contained 1 μL of cDNA, 0.5 μL of primer at 5 μM, 4.75 μl H 2 0, and 6.25 μL of SYBR Green Master Mix (Applied Biosystems). Reactions were amplified on an ABI-7900HT using standard parameters. Transcripts were quantitated by comparative C T method and normalized to TBP. A melting curve analysis was performed to verify the specificity of the amplified PCR products. The following primers were used: TBP: forward CCACTCACAGACTCTCACAAC, reverse CTGCGGTA-CAATCCCAGAACT; PDGF-a: forward CCAGCGACTCCTGGAGATAGA, reverse CTTCTCGGGCACATGCTTAGT, PDGF-b: forward TCTCTGCTGCTACCTGCGT, reverse GTGGGAGCGGGTCATGTTC, PDGF-c: forward ATTCACAGCCCAA-GGTTTCCT, reverse GGGTCTTCAAGCCCAAATCTTT, PDGF-d: forward CCG-GCTCATCTTTGTCTACAC, reverse CAAGTCTGTGAGGTGATTGCTC, PDGFRα: forward GCAAAGGCATCACAATGCTGG, reverse GCACATTCGTAATCTCCA-CTGTC, PDGFRβ: forward AGACACGGGAGAATACTTTTGC, reverse AGTTCC-TCGGCATCATTAGGG.
